Biocompatible Nanoparticles with Aggregation Induced Emission Characteristics as Fluorescent Bioprobes and Methods of Using the Same for in Vitro and in Vivo Imaging
Patent Information:
1. Filing Country: China
Application No: 201280042771.6
Filing Date: 03 March 2014
Patent No: ZL201280042771.6
Issue Date: 30 November 2016
2. Filing Country: Singapore
Application No: 11201400944Q
Filing Date: 25 March 2014
Patent No: 11201400944Q
Issue Date: 15 August 2016
3. Filing Country: USA
Application No: 14/342074
Filing Date: 28 February 2014
Patent No:
Issue Date:
4. Filing Country: China
Application No: 201610234837.1
Filing Date: 15 April 2016
Patent No:
Issue Date:
5. Filing Country: Singapore
Application No: 10201602988V
Filing Date: 15 April 2016
Patent No:
Issue Date:
Inventor 1: Prof. Benzhong, TANG
Inventor 2: Dr. Jianzhao, LIU
Inventor 3: Prof. Bin, LIU
Inventor 4: Mr. Haibin, SHI
Inventor 5: Mr. Jun Long, GENG
Inventor 6: Dr. Tsz Kin, KWOK

Two types of peptide-conjugated aggregation-induced emission (AIE) fluorogen probes, namely a c-RGD conjugated tetraphenylsilole (TPS-2cRGD) probe and a DEVD peptide-conjugated tetraphenylethene (TPE) probe (AcDEVDK-TPE) have been designed. These probes are initially non-fluorescent due to their good water solubility. Upon addition of the corresponding proteins, specific binding between TPS-2cRGD and integrin ?\V?]3 can significantly restrict the molecular rotations of silole core, leading to fluorescence turn-on of the probe. These fluorescence turn-on features allow protein detection both in solution and in cells. Preliminary testing shows that TPS-2cRGD probe could not only be used for detection of integrin ?\V?]3-positive cancer cells but also has the potential to trace the internalization of integrin ?\V?]3 in real-time manner. Additionally, AcDEVDK-TPE is not only capable of monitoring the activities of caspase-3/caspase-7 but would also be suitable for cell apoptosis study. This invention is fundamental and would open up a new avenue for the development of AIE-active biocompatible probes for clinical cancer imaging and diagnostics.
Potential Application   Advantage
Conventional commercial fluorescent probes have the problem of self-quenching and high fluorescent background. This series of fluorescence turn-on probes have the following competitive advantages when compared with the conventional probes:
•Easy to synthesize
•Low preparation cost
•High fluorescence contrast
•High sensitivity
•Stable at ambient conditions
•Easy to store
Market for this invention is promising. Collaboration partners could be medical device manufacturers which focus on fluorescence imaging technology.
Patent documents are available at [], and can be viewed by inserting patent no., application no. or TTC code <TTC Code> into the corresponding field.
Contact information :
Ms Shirley Woo
(852) 2358 7918
HKUST R and D Corporation Ltd
(852) 2358 7917
Technology Transfer Center
香港九龍清水灣 香港科技大學